Mezzion Pharma Co., Ltd.
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
140410 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강남구 삼성로 570 석천빌딩 7층, 서울특별시
- Website:
- https://mezzion.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics, with a particular emphasis on rare diseases. The company's primary efforts are centered on its drug candidate, udenafil, for various medical conditions. A key initiative is the development of udenafil for adolescents living with Fontan circulation, a rare congenital heart condition, supported by a large-scale Phase 3 clinical trial (FUEL-2). Mezzion's pipeline also includes potential treatments for pulmonary arterial hypertension (PAH), portal hypertension, and erectile dysfunction. The company's business model involves developing pharmaceutical products and out-licensing them for international markets.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Mezzion Pharma Co., Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all Mezzion Pharma Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Mezzion Pharma Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
